## FORM 4

## **UNITED STATES**

Washington, D.C. 20549

S	SECU	RII	ILS	AND	ΕX	CHANG	F COM	IMISSION	ı

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Hashim Mir					2. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [ RANI ]							eck all applic Director	able)	Person(s) to Is	)wner	
(Last) (First) (Middle) 2051 RINGWOOD AVE					3. Date of Earliest Transaction (Month/Day/Year) 05/23/2025								Officer (give title Other (specify below)  Chief Scientific Officer			
(Street) SAN JOSE CA 95131					4. If Amendment, Date of Original Filed (Month/Day/Year)						Lin	dividual or Joint/Group Filing (Check Applicable )  Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	state)	(Zip)	Davisas	· O		- 4 -				f D-	6: . : . !	0			
1. Title of Security (Instr. 3) 2. Tran				2. Transact	2A. Deemed Execution Date,			quired, Disposed of, or Benefic  3. Transaction Code (Instr. 8)  4. Securities Acquired (A) (Disposed Of (D) (Instr. 3, 4)			ed (A) or	5. Amour Securities Beneficia Owned Fe	s Form (D) o ollowing (I) (In	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount (A) or (D)		Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)
			Table II - E					uired, Di , options					Owned			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, irity or Exercise (Month/Day/Year) if any		Code	saction (Instr.	Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	Ownersh Form: y Direct (D) or Indirect (I) (Instr.	Beneficial Ownership (Instr. 4)		
					v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	11(3)	
Stock Option (Right to Buy)	\$0.6168	05/23/2025		A		325,000		(1)	0:	5/22/2035	Class A Common Stock	325,000	\$0	325,000	) D	

## **Explanation of Responses:**

1. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from May 23, 2025.

05/23/2025

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.